Cargando…
Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is common in elderly people and is increasing in prevalence. No specific treatment for this condition exists. Coenzyme Q10 (CoQ10) is an essential cofactor for energy production, with reduced levels being noted in HF. Previous studie...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885873/ https://www.ncbi.nlm.nih.gov/pubmed/34826125 http://dx.doi.org/10.1007/s40268-021-00372-1 |
_version_ | 1784660538281689088 |
---|---|
author | Samuel, Tal Y. Hasin, Tal Gotsman, Israel Weitzman, Tanya Ben Ivgi, Fanny Dadon, Ziv Asher, Elad Amir, Offer Glikson, Michael Alcalai, Ronny Leibowitz, David |
author_facet | Samuel, Tal Y. Hasin, Tal Gotsman, Israel Weitzman, Tanya Ben Ivgi, Fanny Dadon, Ziv Asher, Elad Amir, Offer Glikson, Michael Alcalai, Ronny Leibowitz, David |
author_sort | Samuel, Tal Y. |
collection | PubMed |
description | BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is common in elderly people and is increasing in prevalence. No specific treatment for this condition exists. Coenzyme Q10 (CoQ10) is an essential cofactor for energy production, with reduced levels being noted in HF. Previous studies have suggested a possible role for CoQ10 in the treatment of HF. This study examined the effect of CoQ10 supplementation on diastolic function in HFpEF patients. METHODS: We conducted a prospective, randomized, double-blind, placebo-controlled trial including patients aged > 55 years presenting with New York Heart Association class II–IV heart failure symptoms and left ventricular ejection fraction > 50%, with impaired diastolic function. Echocardiography and levels of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) were performed at baseline and following 4 months of CoQ10 or placebo supplementation. RESULTS: A total of 39 patients were enrolled—19 in the CoQ10 group and 20 in the placebo group. Baseline clinical characteristics were similar between groups, while compliance was high and also similar between the CoQ10 and placebo groups. There was no significant effect of treatment on indices of diastolic function (difference in the lateral E/e' ratio: −0.86 ± 6.57 in the CoQ10 group, +0.18 ± 3.76 in the placebo group; p = 0.561) or on serum NT-proBNP levels (− 72 pg/mL vs. − 42 pg/mL; p = 0.195). CONCLUSIONS: In this pilot trial in elderly patients with HFpEF, treatment with CoQ10 did not significantly affect echocardiographic indices of diastolic function and serum NT-proBNP levels. TRIAL REGISTRATION: This trial was registered in the US National Institutes of Health Clinical Trials Registry (ClinicalTrials.gov identifier: NCT02779634). |
format | Online Article Text |
id | pubmed-8885873 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-88858732022-03-08 Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Samuel, Tal Y. Hasin, Tal Gotsman, Israel Weitzman, Tanya Ben Ivgi, Fanny Dadon, Ziv Asher, Elad Amir, Offer Glikson, Michael Alcalai, Ronny Leibowitz, David Drugs R D Original Research Article BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is common in elderly people and is increasing in prevalence. No specific treatment for this condition exists. Coenzyme Q10 (CoQ10) is an essential cofactor for energy production, with reduced levels being noted in HF. Previous studies have suggested a possible role for CoQ10 in the treatment of HF. This study examined the effect of CoQ10 supplementation on diastolic function in HFpEF patients. METHODS: We conducted a prospective, randomized, double-blind, placebo-controlled trial including patients aged > 55 years presenting with New York Heart Association class II–IV heart failure symptoms and left ventricular ejection fraction > 50%, with impaired diastolic function. Echocardiography and levels of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) were performed at baseline and following 4 months of CoQ10 or placebo supplementation. RESULTS: A total of 39 patients were enrolled—19 in the CoQ10 group and 20 in the placebo group. Baseline clinical characteristics were similar between groups, while compliance was high and also similar between the CoQ10 and placebo groups. There was no significant effect of treatment on indices of diastolic function (difference in the lateral E/e' ratio: −0.86 ± 6.57 in the CoQ10 group, +0.18 ± 3.76 in the placebo group; p = 0.561) or on serum NT-proBNP levels (− 72 pg/mL vs. − 42 pg/mL; p = 0.195). CONCLUSIONS: In this pilot trial in elderly patients with HFpEF, treatment with CoQ10 did not significantly affect echocardiographic indices of diastolic function and serum NT-proBNP levels. TRIAL REGISTRATION: This trial was registered in the US National Institutes of Health Clinical Trials Registry (ClinicalTrials.gov identifier: NCT02779634). Springer International Publishing 2021-11-26 2022-03 /pmc/articles/PMC8885873/ /pubmed/34826125 http://dx.doi.org/10.1007/s40268-021-00372-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Article Samuel, Tal Y. Hasin, Tal Gotsman, Israel Weitzman, Tanya Ben Ivgi, Fanny Dadon, Ziv Asher, Elad Amir, Offer Glikson, Michael Alcalai, Ronny Leibowitz, David Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial |
title | Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial |
title_full | Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial |
title_fullStr | Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial |
title_full_unstemmed | Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial |
title_short | Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial |
title_sort | coenzyme q10 in the treatment of heart failure with preserved ejection fraction: a prospective, randomized, double-blind, placebo-controlled trial |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885873/ https://www.ncbi.nlm.nih.gov/pubmed/34826125 http://dx.doi.org/10.1007/s40268-021-00372-1 |
work_keys_str_mv | AT samueltaly coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial AT hasintal coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial AT gotsmanisrael coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial AT weitzmantanya coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial AT benivgifanny coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial AT dadonziv coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial AT asherelad coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial AT amiroffer coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial AT gliksonmichael coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial AT alcalaironny coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial AT leibowitzdavid coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial |